BCWORLD PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,170 KRW | -0.96% |
|
+1.31% | -4.49% |
| Sales 2022 | 72.7B 52.85M 4.41B | Sales 2023 | 75.11B 54.61M 4.55B | Capitalization | 54.51B 39.63M 3.3B |
|---|---|---|---|---|---|
| Net income 2022 | 281M 204K 17.03M | Net income 2023 | 2.63B 1.91M 160M | EV / Sales 2022 | 2.17 x |
| Net Debt 2022 | 86.2B 62.67M 5.22B | Net Debt 2023 | 80.67B 58.65M 4.89B | EV / Sales 2023 | 1.8 x |
| P/E ratio 2022 |
257
x | P/E ratio 2023 |
20.7
x | Employees | 304 |
| Yield 2022 |
1.18% | Yield 2023 |
-
| Free-Float | 55.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.96% | ||
| 1 week | +1.31% | ||
| Current month | -8.73% | ||
| 1 month | -8.73% | ||
| 3 months | -4.34% | ||
| 6 months | -1.12% | ||
| Current year | -4.49% |
1 week
6 120.00
6 290.00
1 month
5 760.006 760.00
Current year
5 760.007 460.00
1 year
5 600.007 520.00
3 years
5 100.0023 050.00
5 years
5 100.0033 800.00
10 years
5 100.0034 898.57
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Han Hong
CEO | Chief Executive Officer | 66 | 01/06/01 |
Seung-Cheol Lee
BRD | Director/Board Member | 66 | 18/06/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kook-Hyun Kim
BRD | Director/Board Member | 59 | 24/17/24 |
Seong-Han Hong
CEO | Chief Executive Officer | 66 | 01/06/01 |
Seung-Cheol Lee
BRD | Director/Board Member | 66 | 18/06/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 6,170 | -0.96% | 4,491 |
| 26/24/26 | 6,230 | +0.32% | 4,117 |
| 25/24/25 | 6,210 | -0.80% | 1,922 |
| 24/24/24 | 6,260 | +0.32% | 3,573 |
| 23/24/23 | 6,240 | +2.46% | 8,463 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
BCWorldPharm Co Ltd is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The Company's products include anesthetic pain medication such as cancer pain treatment, muscle relaxants, anesthesia and pain relief drugs; circulation contracts such as hypertension and hyperlipidemia; antibiotics such as tuberculosis treatment; other prescription drugs such as peptic ulcer and osteoporosis. In addition, the Company develops improved drugs and new products.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.49% | 38.19M | |
| +20.81% | 43.34B | |
| +22.37% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -10.55% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.22B |
- Stock Market
- Equities
- A200780 Stock
